Subtype
Glioblastoma
CI-CAN-00000934GBMExplore in graph →
486 active trials2 approved drugs43 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000934GBMExplore in graph →
Clinical trials
1,750 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (281)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02206230 | Trial of Hypofractionated Radiation Therapy for Glioblastoma | completed | Phase 2 | 133 | AHS Cancer Control AlbertaOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT01811498 | Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM | completed | Phase 1 / Phase 2 | 31 | Northwell HealthOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT03616860 |
| Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption for Treatment of Glioma |
| completed |
| N/A |
| 14 |
| InSightecINDUSTRY |
| 1 |
| Jan 23, 2024 |
| clinicaltrials |
| NCT02457845 | HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors | completed | Phase 1 | 13 | Gregory K. Friedman, MDOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT01383135 | Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2 | completed | Early Phase 1 | 27 | Stanford UniversityOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT04552886 | Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma | completed | Phase 1 | 17 | The Cooper Health SystemOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT02684058 | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | completed | Phase 2 | 151 | Novartis PharmaceuticalsINDUSTRY | 20 | Dec 13, 2023 | clinicaltrials |
| NCT01421524 | Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma | completed | Phase 1 | 271 | CelgeneINDUSTRY | 5 | Dec 12, 2023 | clinicaltrials |
| NCT02060890 | Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma(TGEN) | completed | — | 20 | University of California, San FranciscoOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT03027388 | Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma | completed | Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Nov 22, 2023 | clinicaltrials |
| NCT01957956 | Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | completed | Early Phase 1 | 21 | Mayo ClinicOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02315534 | A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma | completed | Phase 1 / Phase 2 | 34 | Sumitomo Pharma America, Inc.INDUSTRY | 2 | Nov 15, 2023 | clinicaltrials |
| NCT03149003 | A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy | completed | Phase 3 | 221 | Sumitomo Pharma America, Inc.INDUSTRY | 5 | Nov 15, 2023 | clinicaltrials |
| NCT02498665 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | completed | Phase 1 | 24 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT03557372 | Mathematical Model-Adapted Radiation In Glioblastoma | completed | N/A | 14 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT02658981 | Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) | completed | Phase 1 | 63 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT01491893 | PVSRIPO for Recurrent Glioblastoma (GBM)(PVSRIPO) | completed | Phase 1 | 61 | Istari Oncology, Inc.INDUSTRY | 1 | Sep 28, 2023 | clinicaltrials |
| NCT03158389 | NCT Neuro Master Match - N²M² (NOA-20)(N²M²) | completed | Phase 1 / Phase 2 | 228 | University Hospital HeidelbergOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05873946 | Assessing the Effectiveness of 2D Non-Navigated Intraoperative Ultrasound in Glioma Surgery(2D-ioUS-Glio) | completed | — | 99 | Hospital del Rio HortegaOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT04119674 | Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 33 | Zhejiang Cancer HospitalOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT02386826 | INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme | completed | Phase 1 | 65 | SCRI Development Innovations, LLCOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT01493219 | Biomarkers for Prognosis of Glioblastoma (GBM) | completed | — | 19 | University of NebraskaOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT00751270 | Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas(BrTK01) | completed | Phase 1 | 15 | Candel Therapeutics, Inc.INDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT01259869 | A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression | completed | Phase 2 | 34 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 22, 2023 | clinicaltrials |
| NCT05039346 | Quality of Life and Patient Needs in Advanced High Grade Gliomas | completed | — | 55 | Henry Ford Health SystemOTHER | 0 | Aug 14, 2023 | clinicaltrials |
| NCT02619864 | mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme | completed | Phase 1 | 15 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT02330991 | A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse | completed | Phase 2 | 204 | Beijing Sanbo Brain HospitalOTHER | 0 | Jul 24, 2023 | clinicaltrials |
| NCT04814329 | Glioblastoma Response Prediction to Apatinib | completed | — | 18 | Beijing Sanbo Brain HospitalOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT05718466 | Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy | completed | Phase 3 | 35 | Henry Ford Health SystemOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT01290692 | Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma | completed | Phase 2 | 14 | TVAX BiomedicalINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT03360708 | Vaccine Therapy in Treating Patients With Recurrent Glioblastoma | completed | Early Phase 1 | 20 | Mayo ClinicOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT03726515 | CART-EGFRvIII + Pembrolizumab in GBM | completed | Phase 1 | 7 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02661282 | Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma | completed | Phase 1 / Phase 2 | 65 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT02366728 | DC Migration Study for Newly-Diagnosed GBM(ELEVATE) | completed | Phase 2 | 64 | Mustafa Khasraw, MBChB, MD, FRCP, FRACPOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT00662506 | Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2023 | clinicaltrials |
| NCT01081223 | Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma | completed | Phase 1 / Phase 2 | 12 | TVAX BiomedicalINDUSTRY | 1 | Jun 1, 2023 | clinicaltrials |
| NCT02238496 | Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas | completed | Phase 1 | 10 | Andrew B Lassman, MDOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT02751138 | Determination of Immune Phenotype in Glioblastoma Patients | completed | — | 100 | University of UlmOTHER | 1 | May 16, 2023 | clinicaltrials |
| NCT03618667 | GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification | completed | Phase 2 | 13 | Samsung Medical CenterOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT02573324 | A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification(Intellance1) | completed | Phase 3 | 691 | AbbVieINDUSTRY | 28 | May 11, 2023 | clinicaltrials |
| NCT03860376 | Ex Vivo Drug Sensitivity Testing and Mutation Profiling | completed | — | 25 | Florida International UniversityOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT04091503 | Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma | completed | Phase 1 | 30 | Center Trials & Treatment EuropeNETWORK | 3 | Apr 25, 2023 | clinicaltrials |
| NCT02444546 | Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors | completed | Phase 1 | 6 | Mayo ClinicOTHER | 1 | Apr 24, 2023 | clinicaltrials |
| NCT03849105 | 131I-IPA and Concurrent XRT in Recurrent GBM(IPAX-1) | completed | Phase 1 / Phase 2 | 10 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 3 | Apr 14, 2023 | clinicaltrials |
| NCT04630379 | Early Integration of Palliative Care Using the BEACON PROQOL in Patients With High Grade Glioma and Their Caregivers | completed | N/A | 16 | Mayo ClinicOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT05171127 | Differentiation Between Healthy Cerebral Tissue and Tumor Tissue Using a Tissue Sensing Instrument | completed | — | 31 | Karolinska University HospitalOTHER | 1 | Mar 9, 2023 | clinicaltrials |
| NCT04205357 | Sulfasalazine and Stereotactic Radiosurgery for Recurrent Glioblastoma(SAS-GKRS) | completed | Phase 1 | 24 | Haukeland University HospitalOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT01269424 | BG & TMZ Therapy of Glioblastoma Multiforme | completed | Phase 1 | 10 | Stanton Gerson MDOTHER | 1 | Mar 2, 2023 | clinicaltrials |
| NCT03867123 | A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients | completed | Phase 1 | 18 | Laminar PharmaceuticalsINDUSTRY | 1 | Feb 21, 2023 | clinicaltrials |
| NCT02022384 | Immunophenotyping From Blood of Patients With Malignant Gliomas | completed | — | 50 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Feb 16, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jan 31, 2024source: clinicaltrials